Personalized Medicine’s Coming of Age Story
This article was originally published in RPM Report
CDER Director Janet Woodcock is ready to declare victory for personalized medicine reaching the mainstream. That means it is time to move onto new challenges in drug development, such as inter-company collaboration.
You may also be interested in...
Vertex’ cystic fibrosis research is the recipient of the first two “Breakthrough” designations issued by FDA. That underscores the likelihood that the primary value of the new pathway will be as a badge for investors. And that’s probably a good thing.
FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control
FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.
US House of Representatives if moving forward with a bill to respond to advocacy from ALS patients for more attention from FDA. The bill focuses on planning and scientific support, not new pathways.